Blog

cancer patient end-of-life expenditures

 July 23, 2018

In the News: July 19–26

By

This week: Variation in end-of-life expenditures for cancer patients; leading biotech companies targeting cancer with precision medicine; and inpatient utilization continues to slow.

  • Follow Sg2 on Facebook
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn
  • Share
"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube